Association of the Presence of Anti–Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome

Truchetet, Marie-Élise; Dublanc, Stéphanie; Barnetche, Thomas; Vittecoq, Olivier; Mariette, Xavier; Richez, Christophe; Blanco, Patrick; Mähler, Michael; Contin‐Bordes, Cécile; Schaeverbeke, Thierry

doi:10.1002/art.40237

Cited by 57 publications

(58 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We read with interest the article by Truchetet et al concerning the presence of anti–carbamylated protein antibodies (anti‐CarP) in patients with early arthritis from a French cohort. They found that anti‐CarP positivity was associated with higher disease activity and inflammation at baseline.…”

mentioning

confidence: 99%

Anti–Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis—A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al

Derksen

Trouw

Huizinga

et al. 2018

Arthritis & Rheumatology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Anti–Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis—A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al

Derksen

Trouw

Huizinga

et al. 2018

Arthritis & Rheumatology

View full text Add to dashboard Cite

“…However, in individuals who have already progressed to the stage of arthralgia, anti‐CarP did not have an additive value to ACPA and RF in predicting arthritis onset . Once disease has developed, the value of anti‐CarP regains its importance: The presence of anti‐CarP has been independently associated with higher disease activity at baseline and over time, as well as with radiographic damage . At baseline, a broad autoantibody profile regarding different isotypes of RF, ACPA, and anti‐CarP is associated with early treatment response; but the importance of this broad profile diminishes over time .…”

Section: Clinical Relevance Of Autoantibodies In Ramentioning

confidence: 97%

“…The presence of anti-CarP has been independently associated with higher disease activity at baseline and over time, 86,87 as well as with radiographic damage. 88,89 At baseline, a broad autoantibody profile regarding different isotypes of RF, ACPA, and anti-CarP is associated with early treatment response; but the importance of this broad profile diminishes over time.…”

Section: Clini C Al Rele Van Ce Of Autoantibod Ie S In R Amentioning

confidence: 99%

Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology

Volkov

Schie

Woude

2019

Immunological Reviews

119

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. In the last few decades, new insights into RA‐specific autoantibodies and B cells have greatly expanded our understanding of the disease. The best‐known autoantibodies in RA—rheumatoid factor (RF) and anti‐citrullinated protein antibodies (ACPA)—are present long before disease onset, and both responses show signs of maturation around the time of the first manifestation of arthritis. A very intriguing characteristic of ACPA is their remarkably high abundance of variable domain glycans. Since these glycans may convey an important selection advantage of citrulline‐reactive B cells, they may be the key to understanding the evolution of the autoimmune response. Recently discovered autoantibodies targeting other posttranslational modifications, such as anti‐carbamylated and anti‐acetylated protein antibodies, appear to be closely related to ACPA, which makes it possible to unite them under the term of anti‐modified protein antibodies (AMPA). Despite the many insights gained about these autoantibodies, it is unclear whether they are pathogenic or play a causal role in disease development. Autoreactive B cells from which the autoantibodies originate have also received attention as perhaps more likely disease culprits. The development of autoreactive B cells in RA largely depends on the interaction with T cells in which HLA “shared epitope” and HLA DERAA may play an important role. Recent technological advances made it possible to identify and characterize citrulline‐reactive B cells and acquire ACPA monoclonal antibodies, which are providing valuable insights and help to understand the nature of the autoimmune response underlying RA. In this review, we summarize what is currently known about the role of autoantibodies and autoreactive B cells in RA and we discuss the most prominent hypotheses aiming to explain the origins and the evolution of autoimmunity in RA.

show abstract

“…Another promising usage is the discrimination of patients with a poor prognosis. Anti-CarP Ab is a risk factor for future joint destruction independent of ACPA [1,[33][34][35][36][37]. A previous study reported that the anti-carbamylated albumin antibody was associated with a history of cardiovascular disease (CVD) [15] and anti-CarP Ab was associated with multiple indices of arteriosclerosis [38].…”

Section: Other Possibilities For Anti-carp Ab In Clinical Settingsmentioning

confidence: 99%

Clinical and etiological meaning of anti-carbamylated protein antibodies in rheumatoid arthritis

Nakabo

2018

Immunological Medicine

View full text Add to dashboard Cite

Association of the Presence of Anti–Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome

Cited by 57 publications

References 33 publications

Anti–Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis—A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al

Anti–Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis—A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al

Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology

Clinical and etiological meaning of anti-carbamylated protein antibodies in rheumatoid arthritis

Contact Info

Product

Resources

About